Treatment of HCV genotype (GT) 2-infected Japanese patients with paritaprevir (NS3/4A inhibitor boosted with ritonavir) and ombitasvir (NS5A inhibitor) without ribavirin for 12 weeks in the phase 2 study M12-536, and with ribavirin for 16 weeks in phase 3 study GIFT II resulted in SVR rates of 72.2% to 91.5%. Overall, 11 out of 125 patients with GT2a and 37 out of 79 patients with GT2b infection experienced virologic failure. The prevalence of baseline polymorphisms in NS3 and NS5A and their the impact on treatment outcome, as well as the development of viral resistance in GT2-infected patients experiencing virologic failure were evaluated by HCV NS3 and NS5A population and clonal sequence analyses. Baseline polymorphisms in NS3 that confer resistance to paritaprevir were rare in both GT2a-and GT2b-infected patients, while baseline polymorphisms in NS5A that confer resistance to ombitasvir were detected in 11.2% and 14.1% of the GT2a-and GT2b-infected patients, respectively. There was no significant impact of baseline polymorphisms on treatment outcome in Japanese patients. The most common treatment-emergent substitutions at the time of virologic failure occurred at amino acid positions 168 in NS3 and 28 in NS5A in both GT2a-and GT2b-infected patients. Although there was a higher rate of virologic failure in patients with GT2b infection, the resistance analyses presented in this report support the conclusion that testing for baseline resistance-associated polymorphisms is not warranted for HCV GT2-infected patients treated with a regimen of ombitasvir/paritaprevir/ritonavir + ribavirin for 16 weeks.
Treatment of HCV genotype (GT) 2-infected Japanese patients with paritaprevir (NS3/4A
inhibitor boosted with ritonavir) and ombitasvir (NS5A inhibitor) without ribavirin for 12 weeks in the phase 2 study M12-536, and with ribavirin for 16 weeks in phase 3 study GIFT II resulted in SVR rates of 72.2% to 91.5%. Overall, 11 out of 125 patients with GT2a and 37 out of 79 patients with GT2b infection experienced virologic failure. The prevalence of baseline polymorphisms in NS3 and NS5A and their the impact on treatment outcome, as well as the development of viral resistance in GT2-infected patients experiencing virologic failure were evaluated by HCV NS3 and NS5A population and clonal sequence analyses. Baseline polymorphisms in NS3 that confer resistance to paritaprevir were rare in both GT2a-and GT2b-infected patients, while baseline polymorphisms in NS5A that confer resistance to ombitasvir were detected in 11.2% and 14.1% of the GT2a-and GT2b-infected patients, respectively. There was no significant impact of baseline polymorphisms on treatment outcome in Japanese patients. The most common treatment-emergent substitutions at the time of virologic failure occurred at amino acid positions 168 in NS3 and 28 in NS5A in both GT2a-and GT2b-infected patients. Although there was a higher rate of virologic failure in patients with GT2b infection, the resistance analyses presented in this report support the conclusion that testing for baseline resistance-associated polymorphisms is not warranted for HCV GT2-infected patients treated with a regimen of ombitasvir/paritaprevir/ritonavir + ribavirin for 16 weeks. 1 HCV is genetically diverse and classified into 7 confirmed genotypes and 67 subtypes, 2 of which genotype (GT) 2 accounts for 9% of global infections. 3 Japan has a high distribution of HCV infections in Japan has changed over time, and recent studies have reported a decrease in GT1 prevalence and an increase in GT2 prevalence in the HCV-infected patient population which was correlated with differences in transmission routes, especially for individuals born after 1970 where <50% of infections were reported as GT1b. 4, 5 Given that approximately 70% of HCC cases are caused by HCV in Japan, and that HCC prevalence has increased over the past 50 years, 4, 6 direct-acting antiviral (DAA) therapies are needed to treat both HCV GT1 and GT2 infections in Japan.
Several DAA-based therapies with high sustained virologic response (SVR) rates at post-treatment week 12 (SVR 12 ) are approved for the treatment of HCV GT1 infection in Japan. [7] [8] [9] [10] For HCV GT2 infection, the standard of care was previously a combination of pegylated interferon alpha (pegIFN) plus ribavirin (RBV) for 24 weeks, which demonstrated SVR rates of 71-80% in large clinical trials worldwide. [11] [12] [13] The first IFN-free DAA regimen
for HCV GT2 infection with high SVR 12 rates of 93-98% was the combination of the NS5B nucleotide polymerase inhibitor sofosbuvir (SOF) plus RBV for 12 weeks, 14, 15 approved for the treatment of GT2-infected patients in 2015. 16 A treatment regimen of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) plus RBV for 16 weeks was recently approved for the treatment of GT2-infected patients in Japan.
Ombitasvir is an HCV NS5A inhibitor 17 for the treatment of HCV GT2b infection in study M12-536, extended treatment duration of 16 weeks and the addition of RBV to the treatment regimen were evaluated in phase 3 study GIFT-II.
The Japanese GIFT-II study reported SVR 12 rates of 91.5% and 75.0%, respectively, in treatment-naïve and treatment-experienced HCV GT2-infected Japanese patients without cirrhosis who received co-formulated OBV/PTV/r plus RBV for 16 weeks. 20 The current report was designed as a comprehensive clinical virology resistance analysis for GT2-infected Japanese patients enrolled in clinical studies M12-536 or GIFT-II. This analysis examined the GT2 subtype prevalence in M12-536 and GIFT-II, assessed the impact of baseline polymorphisms on SVR rates, and analyzed the development and persistence of viral resistance amino acid substitutions in Japanese GT2-infected patients who experienced virologic failure. The Versant HCV Genotype Inno-LiPA Assay v2.0 (LiPA 2.0) was used to determine HCV genotype for enrollment of patients with chronic HCV GT2 infection for studies M12-536 and GIFT-II, but was unable to identify the viral subtype for the majority of GT2-infected patients.
The preliminary viral subtype was therefore determined by phylogenetic analysis of a 329 nucleotide (nt) region of the NS5B gene that was PCR amplified from baseline samples of HCV GT2-infected patients. 21, 22 Results from this analysis determined the subtype and gene-specific reverse transcriptase (RT)-PCR and nested PCR primer sets for amplification of NS3/4A and NS5A genes from baseline samples. Phylogenetic analyses were subsequently conducted using HCV NS3 (1-543 nt) and NS5A (1-645 nt) nucleotide sequences from baseline samples. Nucleotide sequences for NS3, NS5A, and NS5B
were aligned using the MAFFT sequence alignment method. 23 Phylogenetic trees were constructed using the neighbor-joining tree-building method 24, 25 with the HKY85 nucleotide substitution model 26 and 1000 bootstrapping replicates. 
| Stable HCV replicon cell lines
The non-chimeric GT2a JFH-1 (GenBank accession number AB047639) replicon was bicistronic, and the first cistron contained the 5′ nontranslated region (NTR) from GT2a JFH-1 followed by a firefly luciferase reporter gene and the neomycin phosphotransferase (Neo) gene. This was followed by the EMCV IRES and the second cistron containing the GT2a JFH-1 NS3-NS5B coding region, and 3′
NTR derived from GT2a JFH-1. The NS3 GT2b chimeric stable replicon was generated by insertion of the region encoding the first 251 amino acids of NS3 from a synthetically constructed GT2b protease domain in place of the corresponding region from 2a-JFH- The generation and sequence of the chimeric HCV GT1b Con1
(GenBank accession number AJ238799) subgenomic, transient replicons for NS5A GT2a and 2b were previously described. 19 The 3.2 | Lack of impact of baseline polymorphisms in NS3 and NS5A on SVR NS3 D168E in GT2a, which confers 5.3-fold resistance to paritaprevir, was detected in 1 patient; resistance-conferring baseline polymorphisms were not detected in GT2b (Table 2) .
Baseline polymorphisms in NS5A that confer resistance to ombitasvir in GT2a (T24A/S, F28C, L/M31I, and C92S) were detected at a frequency of 11.2% (14/125). Baseline polymorphisms in NS5A that confer resistance to ombitasvir in GT2b (L28F, L/M31I, and C92S)
were detected in 14.1% (11/78) of the patients ( Table 2 ).
The impact of baseline polymorphisms in NS3 and NS5A on treatment outcome was evaluated for studies M12-536 (Supplementary   Table S2 ) and GIFT-II (Table 3 ) by comparing SVR rates in patients with and without baseline polymorphisms. In study M12-536, SVR 24 rates were similar in patients with or without an NS3 or NS5A polymorphism at baseline with GT2a or GT2b infection (Supplementary Table S2 baseline. There was no significant difference in SVR 12 rates for GT2a-infected patients with M or L amino acids at position 31 in NS5A.
Although there was an increased rate of virologic failure in patients with HCV GT2b infection in study GIFT-II, SVR 12 rates were similar in GT2b-infected patients with or without an NS3 or NS5A polymorphism at baseline (Table 3) . Overall SVR 12 rates were higher for treatment-naïve compared to pegIFN/RBV treatment-experienced GT2b-infected patients without cirrhosis (Table 1) . NS3 polymorphisms conferring resistance to paritaprevir were not detected in any of the non-cirrhotic or cirrhotic GT2b-infected patients at baseline. (Table 4 ).
Nine GT2a-infected patients in study GIFT-II experienced VF (Tables 1 and 4 Table 5 .
| Persistence of treatment-emergent substitutions through post-treatment week 48
Baseline polymorphisms and treatment-emergent substitutions in NS3 and NS5A were monitored for persistence through post-treatment week 48 by population and clonal sequencing analyses (Figure 1) . GT, genotype; NA, not applicable as there were no GT2a VFs in the study arm; TN, treatment-naïve; TE, treatment-experienced to an IFN-containing regimen (IFN alpha, beta, or pegIFN) with or without RBV. 
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